Search

Your search keyword '"Prica, Anca"' showing total 612 results
Start Over Author "Prica, Anca"
612 results on '"Prica, Anca"'

2. Valemetostat for patients with relapsed or refractory peripheral T-cell lymphoma (VALENTINE-PTCL01): a multicentre, open-label, single-arm, phase 2 study

Author

Zinzani, Pier Luigi, Izutsu, Koji, Mehta-Shah, Neha, Barta, Stefan K, Ishitsuka, Kenji, Córdoba, Raul, Kusumoto, Shigeru, Bachy, Emmanuel, Cwynarski, Kate, Gritti, Giuseppe, Prica, Anca, Jacobsen, Eric, Feldman, Tatyana, Guillermin, Yann, Ennishi, Daisuke, Yoon, Dok Hyun, Domenech, Eva Domingo, Zain, Jasmine, Wang, Jie, Kim, Jin Seok, Poel, Marjolein van der, Jin, Jin, Wu, Sutan, Chen, Yang, Moriyama, Takaya, Inoue, Ai, Nakajima, Keiko, and Horwitz, Steven M

Published
2024
Full Text
View/download PDF

11. A randomized trial of ibrutinib and R‐GDP prior to stem cell transplant in relapsed diffuse large B‐cell lymphoma.

Author

Kuruvilla, John, Rushton, Christopher, Villa, Diego, Aslam, Muhammad, Prica, Anca, Abdel Samad, Nizar, Doucet, Stephane, Dudebout, Jill, Fleury, Isabelle, Fraser, Graeme, Larouche, Jean‐Francois, Shafey, Mona, Skrabek, Pamela, Skamene, Tanya, Morin, Ryan D., Alcaide, Miguel, Ben‐Neriah, Susana, Lee, David, Winch, Chad, and Shepherd, Lois E.

Subjects
POSITRON emission tomography computed tomography, BRUTON tyrosine kinase, DIFFUSE large B-cell lymphomas, FLUORESCENCE in situ hybridization, INSTITUTIONAL review boards, CUTANEOUS T-cell lymphoma
Abstract

The article discusses a randomized trial comparing ibrutinib-R-GDP (IR-GDP) with R-GDP in adults with relapsed and refractory diffuse large B-cell lymphoma. The study found that IR-GDP led to more documented infections without improving overall response compared to R-GDP. The trial was approved by research ethics boards, and after reviewing toxicity and efficacy, the IR-GDP arm was closed prematurely due to futility. The study highlights the importance of biomarker-driven trials and the evolving landscape of therapy for relapsed and refractory DLBCL. [Extracted from the article]

Published
2024
Full Text
View/download PDF

12. Development and testing of a lymphoma clinical trial-specific frailty index: a secondary analysis of the NCIC-CTG LY.12 clinical trial.

Author

Vijenthira, Abi, Li, Xinzhi, Crump, Michael, Hay, Annette E., Shepherd, Lois, Meyer, Ralph M., Djurfeldt, Marina, Chen, Bingshu E., and Prica, Anca

Subjects
CLINICAL trials, STEM cell transplantation, NON-Hodgkin's lymphoma, FRAILTY, SECONDARY analysis
Abstract

The prevalence of frailty in clinical trials of lymphoma is unknown. We conducted a secondary analysis of the phase III LY.12 trial in which patients with relapsed aggressive non-Hodgkin lymphoma were randomized to different salvage regimens before autologous stem cell transplant. The primary objective was to construct a lymphoma clinical trials-specific frailty index (LyFI) using previously described methods. The secondary objective was to describe the association of frailty withover all and event-free survival (OS, EFS). The LyFI was constructed using 619 patients, and11% (N = 70) were classified as frail. Frailty was associated with EFS (HR 1.94, 95%CI 1.53–2.46) and OS (HR 2.01, 95%CI 1.57–2.58) in univariable analysis, but was only significant as a continuous (not binary) variable in multivariable analysis controlling for prognostic score, suggesting limitations of a FI in this trial population. Future work could validate the FI using clinical assessments and/or apply it to an older trial population. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

14. A Prospective Economic Analysis of Early Outcome Data From the Alliance A041202/ CCTG CLC.2 Randomized Phase III Trial Of Bendamustine-Rituximab Compared With Ibrutinib-Based Regimens in Untreated Older Patients With Chronic Lymphocytic Leukemia

Author

Cheung, Matthew C., Mittmann, Nicole, Owen, Carolyn, Abdel-Samad, Nizar, Fraser, Graeme A.M., Lam, Selay, Crump, Michael, Sperlich, Catherine, van der Jagt, Richard, Prica, Anca, Couban, Stephen, Woyach, Jennifer A., Ruppert, Amy S., Booth, Allison M., Mandrekar, Sumithra J., McDonald, Gail, Shepherd, Lois E., Yen, Hope, Chen, Bingshu E., and Hay, Annette E.

Published
2021
Full Text
View/download PDF

20. Red cell transfusion thresholds in outpatients with myelodysplastic syndromes: Results of a pilot randomized trial RBC‐ENHANCE

Author

Buckstein, Rena, primary, Callum, Jeannie, additional, Prica, Anca, additional, Bowen, David, additional, Wells, Richard A., additional, Leber, Brian, additional, Heddle, Nancy, additional, Chodirker, Lisa, additional, Cheung, Matthew, additional, Mozessohn, Lee, additional, Yee, Karen, additional, Gallagher, Jennifer, additional, Parmentier, Anne, additional, Jamula, Erin, additional, Zhang, Liying, additional, Mamedov, Alex, additional, Stanworth, Simon J., additional, and Lin, Yulia, additional

Published
2024
Full Text
View/download PDF

22. Red cell transfusion thresholds in outpatients with myelodysplastic syndromes: Combined results from two randomized controlled feasibility studies

Author

Buckstein, Rena, primary, Callum, Jeannie, additional, Prica, Anca, additional, Bowen, David, additional, Wells, Richard A., additional, Leber, Brian, additional, Heddle, Nancy, additional, Chodirker, Lisa, additional, Cheung, Matthew, additional, Mozessohn, Lee, additional, Yee, Karen, additional, Gallagher, Jennifer, additional, Parmentier, Anne, additional, Jamula, Erin, additional, McQuilten, Zoe, additional, Wood, Erica M., additional, Weinkov, Robert, additional, Zhang, Liying, additional, Mamedov, Alex, additional, Stanworth, Simon J., additional, and Lin, Yulia, additional

Published
2023
Full Text
View/download PDF

23. Hematopoietic Cell Transplantation Trends and Outcomes in Canada: A Registry-Based Cohort Study

Author

Seftel, Matthew D., primary, Pasic, Ivan, additional, Parmar, Gaganvir, additional, Bucher, Oliver, additional, Allan, David S., additional, Bhella, Sita, additional, Hay, Kevin Anthony, additional, Ikuomola, Oluwaseun, additional, Musto, Grace, additional, Prica, Anca, additional, Richardson, Erin, additional, Truong, Tony H., additional, and Paulson, Kristjan, additional

Published
2023
Full Text
View/download PDF

26. Brentuximab vedotin plus bendamustine in relapsed or refractory Hodgkin's lymphoma: an international, multicentre, single-arm, phase 1–2 trial

Author

O'Connor, Owen A, Lue, Jennifer K, Sawas, Ahmed, Amengual, Jennifer E, Deng, Changchun, Kalac, Matko, Falchi, Lorenzo, Marchi, Enrica, Turenne, Ithamar, Lichtenstein, Renee, Rojas, Celeste, Francescone, Mark, Schwartz, Lawrence, Cheng, Bin, Savage, Kerry J, Villa, Diego, Crump, Michael, Prica, Anca, Kukreti, Vishal, Cremers, Serge, Connors, Joseph M, and Kuruvilla, John

Published
2018
Full Text
View/download PDF

28. Mortality among patients with diffuse large B-cell lymphoma and mental disorders: a population-based study

Author

Gong, Inna Y, primary, Cheung, Matthew C, additional, Chan, Kelvin K W, additional, Arya, Sumedha, additional, Faught, Neil, additional, Calzavara, Andrew, additional, Liu, Ning, additional, Odejide, Oreofe O, additional, Abel, Gregory, additional, Kurdyak, Paul, additional, Raphael, Michael J, additional, Kuczmarski, Thomas, additional, Prica, Anca, additional, and Mozessohn, Lee, additional

Published
2023
Full Text
View/download PDF

29. PB2358: PHASE 1-2 STUDY OF THE SAFETY, PK, PD, AND PRELIMINARY ACTIVITY OF TOLINAPANT IN COMBINATION WITH ORAL DECITABINE/CEDAZURIDINE AND ORAL DECITABINE/CEDAZURIDINE ALONE IN SUBJECTS WITH R/R PTCL

Author

Shortt, Jake, primary, Poligone, Brian, additional, Ribrag, Vincent, additional, Zinzani, Pier Luigi, additional, El-Sharkawi, Dima, additional, Walewski, Jan, additional, Prica, Anca, additional, Wilson, Laksmi, additional, Souza, Sonia, additional, Keer, Harold, additional, Taylor, Jason, additional, and Marchi, Enrica, additional

Published
2023
Full Text
View/download PDF

31. Indolent lymphoma care delivery and outcomes during the COVID‐19 pandemic in Ontario, Canada.

Author

Gong, Inna Y., Prica, Anca, Ante, Zharmaine, Calzavara, Andrew, Krzyzanowska, Monika K., Singh, Simron, Suleman, Adam, Cheung, Matthew C., and Crump, Michael

Subjects
*COVID-19, *COVID-19 pandemic, *EMERGENCY room visits, *PROPORTIONAL hazards models, *LYMPHOMAS, *FEBRILE neutropenia
Abstract

Summary: The treatment pattern and outcomes in patients with indolent B‐cell lymphoma treated during the coronavirus disease 2019 (COVID‐19) pandemic period compared to the prepandemic period are unclear. This was a retrospective population‐based study using administrative databases in Ontario, Canada (follow‐up to 31 March 2022). The primary outcome was treatment pattern; secondary outcomes were death, toxicities, healthcare utilization (emergency department [ED] visit, hospitalization) and SARS‐CoV‐2 outcomes. Adjusted hazard ratios (aHR) from Cox proportional hazards models were used to estimate associations. We identified 4143 patients (1079 pandemic, 3064 prepandemic), with a median age of 69 years. In both time periods, bendamustine (B) + rituximab (BR) was the most frequently prescribed regimen. During the pandemic, fewer patients received R maintenance or completed the full 2‐year course (aHR 0.81, 95% CI 0.71–0.92, p = 0.001). Patients treated during the pandemic had less healthcare utilization (ED visit aHR 0.77, 95% CI 0.68, 0.88, p < 0.0001; hospitalization aHR 0.81, 95% CI 0.70–0.94, p = 0.0067) and complications (infection aHR 0.69, 95% CI 0.57–0.82, p < 0.0001; febrile neutropenia aHR 0.66, 95% CI 0.47–0.94, p = 0.020), with no difference in death. Independent of vaccination, active rituximab use was associated with a higher risk of COVID‐19 complications. Despite similar front‐line regimen use, healthcare utilization and admissions for infection were less in the pandemic cohort. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

32. Red cell transfusion thresholds in outpatients with myelodysplastic syndromes: Combined results from two randomized controlled feasibility studies.

Author

Buckstein, Rena, Callum, Jeannie, Prica, Anca, Bowen, David, Wells, Richard A., Leber, Brian, Heddle, Nancy, Chodirker, Lisa, Cheung, Matthew, Mozessohn, Lee, Yee, Karen, Gallagher, Jennifer, Parmentier, Anne, Jamula, Erin, McQuilten, Zoe, Wood, Erica M., Weinkov, Robert, Zhang, Liying, Mamedov, Alex, and Stanworth, Simon J.

Published
2024
Full Text
View/download PDF

34. Suppl Fig 2 from Targeting the Inducible T-cell Costimulator (ICOS) in Patients with Relapsed/Refractory T-follicular Helper Phenotype Peripheral T-cell and Angioimmunoblastic T-cell Lymphoma

Author

Chavez, Julio C., primary, Foss, Francine M., primary, William, Basem M., primary, Brammer, Jonathan E., primary, Smith, Sonali M., primary, Prica, Anca, primary, Zain, Jasmine M., primary, Tuscano, Joseph M., primary, Shah, Harsh, primary, Mehta-Shah, Neha, primary, Geethakumari, Praveen Ramakrishnan, primary, Wang, Ben X., primary, Zantinge, Stephanie, primary, Wang, Lisa, primary, Zhang, Ling, primary, Boutrin, Anmarie, primary, Zhao, Weiguang, primary, Cheng, Lily, primary, Standifer, Nathan, primary, Hewitt, Lisa, primary, Enowtambong, Enowmpey, primary, Shao, Weiping, primary, Sharma, Shringi, primary, Carlesso, Gianluca, primary, Moscow, Jeffrey A., primary, and Siu, Lillian L., primary

Published
2023
Full Text
View/download PDF

35. Supplementary Data1 from Targeting the Inducible T-cell Costimulator (ICOS) in Patients with Relapsed/Refractory T-follicular Helper Phenotype Peripheral T-cell and Angioimmunoblastic T-cell Lymphoma

Author

Chavez, Julio C., primary, Foss, Francine M., primary, William, Basem M., primary, Brammer, Jonathan E., primary, Smith, Sonali M., primary, Prica, Anca, primary, Zain, Jasmine M., primary, Tuscano, Joseph M., primary, Shah, Harsh, primary, Mehta-Shah, Neha, primary, Geethakumari, Praveen Ramakrishnan, primary, Wang, Ben X., primary, Zantinge, Stephanie, primary, Wang, Lisa, primary, Zhang, Ling, primary, Boutrin, Anmarie, primary, Zhao, Weiguang, primary, Cheng, Lily, primary, Standifer, Nathan, primary, Hewitt, Lisa, primary, Enowtambong, Enowmpey, primary, Shao, Weiping, primary, Sharma, Shringi, primary, Carlesso, Gianluca, primary, Moscow, Jeffrey A., primary, and Siu, Lillian L., primary

Published
2023
Full Text
View/download PDF

36. Suppl Fig 3 from Targeting the Inducible T-cell Costimulator (ICOS) in Patients with Relapsed/Refractory T-follicular Helper Phenotype Peripheral T-cell and Angioimmunoblastic T-cell Lymphoma

Author

Chavez, Julio C., primary, Foss, Francine M., primary, William, Basem M., primary, Brammer, Jonathan E., primary, Smith, Sonali M., primary, Prica, Anca, primary, Zain, Jasmine M., primary, Tuscano, Joseph M., primary, Shah, Harsh, primary, Mehta-Shah, Neha, primary, Geethakumari, Praveen Ramakrishnan, primary, Wang, Ben X., primary, Zantinge, Stephanie, primary, Wang, Lisa, primary, Zhang, Ling, primary, Boutrin, Anmarie, primary, Zhao, Weiguang, primary, Cheng, Lily, primary, Standifer, Nathan, primary, Hewitt, Lisa, primary, Enowtambong, Enowmpey, primary, Shao, Weiping, primary, Sharma, Shringi, primary, Carlesso, Gianluca, primary, Moscow, Jeffrey A., primary, and Siu, Lillian L., primary

Published
2023
Full Text
View/download PDF

37. Suppl Fig 1 from Targeting the Inducible T-cell Costimulator (ICOS) in Patients with Relapsed/Refractory T-follicular Helper Phenotype Peripheral T-cell and Angioimmunoblastic T-cell Lymphoma

Author

Chavez, Julio C., primary, Foss, Francine M., primary, William, Basem M., primary, Brammer, Jonathan E., primary, Smith, Sonali M., primary, Prica, Anca, primary, Zain, Jasmine M., primary, Tuscano, Joseph M., primary, Shah, Harsh, primary, Mehta-Shah, Neha, primary, Geethakumari, Praveen Ramakrishnan, primary, Wang, Ben X., primary, Zantinge, Stephanie, primary, Wang, Lisa, primary, Zhang, Ling, primary, Boutrin, Anmarie, primary, Zhao, Weiguang, primary, Cheng, Lily, primary, Standifer, Nathan, primary, Hewitt, Lisa, primary, Enowtambong, Enowmpey, primary, Shao, Weiping, primary, Sharma, Shringi, primary, Carlesso, Gianluca, primary, Moscow, Jeffrey A., primary, and Siu, Lillian L., primary

Published
2023
Full Text
View/download PDF

38. Statins to prevent early cardiac dysfunction in cancer patients at increased cardiotoxicity risk receiving anthracyclines

Author

Thavendiranathan, Paaladinesh, primary, Houbois, Christian, additional, Marwick, Thomas H, additional, Kei, Tiffanie, additional, Saha, Sudipta, additional, Runeckles, Kyle, additional, Huang, Flora, additional, Shalmon, Tamar, additional, Thorpe, Kevin E, additional, Pezo, Rossanna C, additional, Prica, Anca, additional, Maze, Dawn, additional, Abdel-Qadir, Husam, additional, Connelly, Kim, additional, Chan, Joyce, additional, Billia, Filio, additional, Power, Coleen, additional, Hanneman, Kate, additional, Wintersperger, Bernd J, additional, Brezden-Masley, Christine, additional, and Amir, Eitan, additional

Published
2023
Full Text
View/download PDF

39. Data from Targeting the Inducible T-cell Costimulator (ICOS) in Patients with Relapsed/Refractory T-follicular Helper Phenotype Peripheral T-cell and Angioimmunoblastic T-cell Lymphoma

Author

Chavez, Julio C., primary, Foss, Francine M., primary, William, Basem M., primary, Brammer, Jonathan E., primary, Smith, Sonali M., primary, Prica, Anca, primary, Zain, Jasmine M., primary, Tuscano, Joseph M., primary, Shah, Harsh, primary, Mehta-Shah, Neha, primary, Geethakumari, Praveen Ramakrishnan, primary, Wang, Ben X., primary, Zantinge, Stephanie, primary, Wang, Lisa, primary, Zhang, Ling, primary, Boutrin, Anmarie, primary, Zhao, Weiguang, primary, Cheng, Lily, primary, Standifer, Nathan, primary, Hewitt, Lisa, primary, Enowtambong, Enowmpey, primary, Shao, Weiping, primary, Sharma, Shringi, primary, Carlesso, Gianluca, primary, Moscow, Jeffrey A., primary, and Siu, Lillian L., primary

Published
2023
Full Text
View/download PDF

41. Ibrutinib Plus RCHOP versus RCHOP Only in Young Patients with Activated B-Cell-like Diffuse Large B-Cell Lymphoma (ABC-DLBCL): A Cost-Effectiveness Analysis.

Author

Rho, Hayeong, Jeong, Irene Joo-Hyun, and Prica, Anca

Subjects
DIFFUSE large B-cell lymphomas, QUALITY-adjusted life years, COST effectiveness, MARKOV processes
Abstract

The standard treatment for Diffuse Large B-Cell Lymphoma (DLBCL) is rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (RCHOP). However, many patients require subsequent treatment after relapsed disease. The ABC subtype of DLBCL (ABC-DLBCL) has a worse prognosis, and the PHOENIX trial explored adding ibrutinib to RCHOP for this patient population. The trial showed favorable outcomes for younger patients, and our study aimed to inform clinical decision-making via a cost-effectiveness model to compare RCHOP with and without ibrutinib (I-RCHOP). A Markov decision analysis model was designed to compare the treatments for patients younger than 60 years with ABC-DLBCL. The model considered treatment pathways, adverse events, relapses, and death, incorporating data on salvage treatments and novel therapies. The results indicated that I-RCHOP was more cost-effective, with greater quality-adjusted life years (QALY, 15.48 years vs. 14.25 years) and an incremental cost-effectiveness ratio (ICER) of CAD 34,111.45/QALY compared to RCHOP only. Sensitivity analyses confirmed the model's robustness. Considering the high market price for ibrutinib, I-RCHOP may be more costly. However, it is suggested as the preferred cost-effective strategy for younger patients due to its benefits in adverse events, overall survival, and quality of life. The decision analytic model provided relevant and robust results to inform clinical decision-making. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

45. Targeting the Inducible T-cell Costimulator (ICOS) in Patients with Relapsed/Refractory T-follicular Helper Phenotype Peripheral T-cell and Angioimmunoblastic T-cell Lymphoma

Author

Chavez, Julio C., primary, Foss, Francine M., additional, William, Basem M., additional, Brammer, Jonathan E., additional, Smith, Sonali M., additional, Prica, Anca, additional, Zain, Jasmine M., additional, Tuscano, Joseph M., additional, Shah, Harsh, additional, Mehta-Shah, Neha, additional, Geethakumari, Praveen Ramakrishnan, additional, Wang, Ben X., additional, Zantinge, Stephanie, additional, Wang, Lisa, additional, Zhang, Ling, additional, Boutrin, Anmarie, additional, Zhao, Weiguang, additional, Cheng, Lily, additional, Standifer, Nathan, additional, Hewitt, Lisa, additional, Enowtambong, Enowmpey, additional, Shao, Weiping, additional, Sharma, Shringi, additional, Carlesso, Gianluca, additional, Moscow, Jeffrey A., additional, and Siu, Lillian L., additional

Published
2023
Full Text
View/download PDF

48. Impact of Geriatric Assessment and Management on Quality of Life, Unplanned Hospitalizations, Toxicity, and Survival for Older Adults With Cancer: The Randomized 5C Trial

Author

Puts, Martine, primary, Alqurini, Naser, additional, Strohschein, Fay, additional, Koneru, Rama, additional, Szumacher, Ewa, additional, Mariano, Caroline, additional, Monette, Johanne, additional, Hsu, Tina, additional, Brennenstuhl, Sarah, additional, McLean, Bianca, additional, Wills, Aria, additional, Berger, Arielle, additional, Amir, Eitan, additional, Romanovsky, Lindy, additional, Li, Anson, additional, Mehta, Rajin, additional, Krzyzanowska, Monika, additional, Elser, Christine, additional, Jang, Raymond, additional, Prica, Anca, additional, Wan-Chow-Wah, Doreen, additional, Pitters, Eric, additional, Emmenegger, Urban, additional, Menjak, Ines B., additional, Bergman, Simon, additional, Lemonde, Manon, additional, Breunis, Henriette, additional, Béland, Francois, additional, and Alibhai, Shabbir M.H., additional

Published
2023
Full Text
View/download PDF

49. International Prognostic Score for Nodular Lymphocyte-Predominant Hodgkin Lymphoma

Author

Binkley, Michael S., primary, Flerlage, Jamie E., additional, Borchmann, Peter, additional, Fuchs, Michael, additional, Hartmann, Sylvia, additional, Eich, Hans Theodor, additional, Savage, Kerry J., additional, Lo, Andrea C., additional, Skinnider, Brian, additional, Akhtar, Saad, additional, Rauf, M. Shahzad, additional, Maghfoor, Irfan, additional, Pinnix, Chelsea, additional, Steiner, Raphael, additional, Milgrom, Sarah A., additional, Vega, Francisco, additional, Alomari, Mohammed, additional, Yang, Xiao-Yin, additional, Collins, Graham, additional, Advani, Ranjana H., additional, Metzger, Monika, additional, Dickinson, Michael, additional, Wirth, Andrew, additional, Tsang, Richard, additional, Prica, Anca, additional, Major, Ajay, additional, Smith, Sonali, additional, Hendrickson, Peter G., additional, Kelsey, Chris R., additional, Hopkins, David, additional, McKay, Pam, additional, Ng, Andrea, additional, Koenig, Julie, additional, Constine, Louis S., additional, Casulo, Carla, additional, Sakthivel, Gukan, additional, Baron, Jonathan, additional, Plastaras, John P., additional, Roberts, Kenneth B., additional, Gao, Sarah, additional, Al Kendi, Jalila, additional, Al Rahbi, Nasser, additional, Balogh, Alex, additional, Levis, Mario, additional, Ricardi, Umberto, additional, Sridhar, Akshay, additional, Torka, Pallawi, additional, Specht, Lena, additional, De Silva, Ravindu, additional, Shah, Nimish, additional, Pickard, Keir, additional, Osborne, Wendy, additional, Blazin, Lindsay J., additional, Henry, Michael, additional, Chang, Isabela, additional, Smith, Christine M., additional, Halperin, Daniel, additional, Miall, Fiona, additional, Brady, Jessica, additional, Mikhaeel, George, additional, Brennan, Bernadette, additional, Penn, Anthony, additional, Senchenko, Mariia Anatolevna, additional, Volchkov, Egor Vasilevich, additional, Reeves, Marie, additional, Hoppe, Bradford S., additional, Terezakis, Stephanie, additional, Talaulikar, Dipti, additional, Della Pepa, Roberta, additional, Picardi, Marco, additional, Kirova, Youlia, additional, Fergusson, Paige, additional, Northend, Michael, additional, Hawkes, Eliza, additional, Lee, Denise, additional, Wong Doo, Nicole, additional, Barraclough, Allison, additional, Opat, Stephen, additional, Cheah, Chan, additional, Salvaris, Ross, additional, Ku, Matthew, additional, Hamad, Nada, additional, Mutsando, Howard, additional, Tedjaseputra, Aditya, additional, Gilbertson, Michael, additional, Marconi, Tamara, additional, Viiala, Nicholas, additional, Palese, Monica, additional, Shankar, Ananth, additional, Maurer, Matthew J., additional, Natkunam, Yasodha, additional, Kelly, Kara M., additional, Eichenauer, Dennis A., additional, and Hoppe, Richard T., additional

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results